Article Text

Download PDFPDF

1019 Interim analysis of 10-year data regarding treatment and prognosis of uterine carcinosarcoma cases across the thames valley cancer alliance network
  1. SL Smyth1,
  2. A Gkorila2,
  3. A Mcculloch3,
  4. P Tupper4,
  5. A Sattar2,
  6. N Sadeghi2,
  7. S Spencer2,
  8. K Zarrindej2,
  9. V Le Thanh2,
  10. J Rencher2,
  11. G Sharma2,
  12. A Kashif2,
  13. M Abdalla2,
  14. S Addley1,
  15. S Siddiki5,
  16. M Alazzam2 and
  17. H Soleymani Majd2
  1. 1Churchill Hospital, Gynaecological Oncology, Oxford, UK
  2. 2John Radcliffe Hospital, Oxford, UK
  3. 3Royal Berkshire Hospital, UK
  4. 4Stoke Mandeville Hospital, UK
  5. 5Great Western Hospital, UK


Introduction/Background*Uterine Carcinosarcoma (UCS) comprises <5% of uterine malignancies, accounting for >15% associated mortality. With no established guidelines, we present our experience to determine optimal treatment and prognosis of UCS.

Methodology We conducted a multicentre retrospective cohort study, including all surgically managed UCS cases between March 2010 and January 2020. Data was collected on FIGO staging and post-operative management, recurrence and survival outcomes.

Result(s)*82 (9.7%) UCS cases were identified. Table 1 demonstrates case staging and management strategies. 23 patients underwent surgery alone due to poor performance status, comorbidities, age or treatment refusal. 15.8% had lymph nodes metastases, which was in keeping with the literature. Recurrence occurred in 47.8% and 77.8% of cases of early and late stage respectively; most frequently in the pelvis, but also commonly in the pelvic lymph nodes and chest. Both recurrence and subsequent death usually occurred within the first 1-2 years following treatment. This retrospective analysis explores for significance in overall and disease free survival between disease stage groups and treatment modalities using univariable and multivariable Cox regression models and Kaplan-Meier curves.

Abstract 1019 Table 1

Treatment modalities of patients with UCS

Abstract 1019 Table 2

Recurrence and survival outcomes of patients with UCS

Conclusion*UCS is highly aggressive and has a poor prognosis. Significant rates of lymph node metastases have implications for adjuvant treatment in addition to high rates of relapse and distant metastases. Without an optimal treatment strategy established, discussions continue regarding adjuvant management as to potential improvements in prognosis. Whilst surgery remains the mainstay, multimodal treatment plans including combination of systemic chemotherapy followed by vaginal brachytherapy may be reasonable to address risks of both local relapse and distant metastases. In view of limited data and few prospective trials, we report on the results of our cancer network in contribution to evaluation of results of care in building a consensus for case management. We stress the importance of an individualised multidisciplinary team approach for management of UCS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.